Abstract��OBJECTIVE Nowadays, recombinant monoclonal antibodies developed as biosimilar domains in application category for Investigational New Drug in domestic. The quality similarity should be prequalified for candidate drug to be developed as biosimilar. Here, the concept of quality biosimilarity was proposed and discussed from reviewer as well as developer. METHODS The challenge of developing and evaluating biosimilar antibodies was emphasized. Then, the domestic sponsor��s common problems were sorted out and critical quality attributes of some originator antibodies were summarized. Lastly, the reasons of holding letter or case rejected were exemplified and analyzed. RESULTS AND CONCLUSION The sponsor are encouraged to conduct comparing exercise by state-of-art analytical technologies to conform the quality similarity between a proposed biosimilar antibody and the originator product, the reviewers should also be very cautious to assess quality differences. Joint efforts and effective communication from researcher and reviewer are critical for promoting development of domestic biosimilar and addressing the unmet medicine need.
������,����,����. ���ڵ�����������ҩ�����������ԡ���˼��[J]. �й�ҩѧ��־, 2017, 52(13): 1194-1200.
LIU Bo-ning, BAI Yu, LUO Jian-hui. Biosimilarity Study Regarding Product Quality of Candidate Recombinant Monoclonal Antibodies as Biosimilars. Chinese Pharmaceutical Journal, 2017, 52(13): 1194-1200.
LIU B N. The progress of therapeutic antibody drug and the industrial key-technology of antibody production . J Chin Biotechnol(�й����﹤����־), 2013, 33(5):132-138.
[2]
UDPA N, MILLION R P. Monoclonal antibody biosimilars . Nat Rev Drug Discov, 2016, 15(1):13-14.
[3]
JACOBS I, PETERSEL D, SHANE L G, et al. Monoclonal antibody and fusion protein biosimilars across therapeutic areas: a systematic review of published evidence . Bio Drugs, 2016, 30(6):489-523.
[4]
NIKOLOV N P, SHAPIRO M A. An FDA perspective on the assessment of proposed biosimilar therapeutic proteins in rheumatology . Nat Rev Rheumatol, 2017, 13(2):123-128.
[5]
SCHELLEKENS H. How similar do��biosimilars�� need to be? . Nat Biotechnol, 2004, 22(11):1357-1359.
[6]
LUO J H, WEI W, XIANG J Z, et al. Comments and suggestions on development and evaluation of biosimilar . Chin Pharm J (�й�ҩѧ��־), 2015, 50(6):473-476
[7]
MCCAMISH M, WOOLLETT G. The state of the art in the development of biosimilars . Clin Pharmacol Ther, 2012, 91(3):405-417.
[8]
LIU B N. Industrial biosimilar development under guidelines . China pharmaceutical news(�й�ҽҩ��), 20150317(A06).
[9]
LEE J F, LITTEN J B, GRAMPP G. Comparability and biosimilarity:considerations for the healthcare provider . Curr Med Res Opin, 2012, 28(6):1053-1058. RAMANAN S, GRAMPP G. Drift, evolution, and divergence in biologics and biosimilars manufacturing . Bio Drugs, 2014, 28(4):363-372. SCHIESTL M, STANGLER T, TORELLA C, et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals . Nat Biotechnol, 2011, 29(4):310-312. KIM S, SONG J, PARK S, et al. Drifts in ADCC-related quality attributes of herceptin(R): impact on development of a trastuzumab biosimilar . MAbs, 2017, 9(4):704-714. EMEA. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance:quality issues . 2014. FDA. Quility Considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product . 2015. WHO. Guidelines on evaluation of similar biotherapeutic products(SBPs) . 2009. WHO. Guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products(SBPs) . 2016. CFDA. Guidelines on Biosimilars:Research, Development and Evaluation(draft) . 2015. TSONG Y, DONG X, SHEN M. Development of statistical methods for analytical similarity assessment . J Biopharm Stat, 2017,27(2):197-205. EMEA. Draft reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development . 2017. JUNG S K, LEE K H, JEON J W, et al. Physicochemical characterization of remsima . MAbs, 2014, 6(5):1163-1177. CHO I H, LEE N, SONG D, et al. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept . MAbs, 2016, 8(6):1136-1155. LIU J, ERIS T, LI C, et al. Assessing analytical similarity of proposed amgen biosimilar ABP 501 to adalimumab . Bio Drugs, 2016, 30(4):321-338. BAI Y, WANG H X, XIE S M, et al. Challengs of pharmaceutical evaluation of biosimilars . Chin Pharm J(�й�ҩѧ��־), 2015,50(6):477-479. VELAYUDHAN J, CHEN Y F, ROHRBACH A, et al. Demonstration of functional similarity of proposed biosimilar ABP 501 to adalimumab . Bio Drugs, 2016, 30(4):339-351. HOFMANN H P, KRONTHALER U, FRITSCH C, et al. Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept . Expert Opin Biol Ther, 2016, 16(10):1185-1195. WEINER G J. Rituximab:mechanism of action . Semin Hematol, 2010, 47(2):115-123. VISSER J, FEUERSTEIN I, STANGLER T, et al. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab . Bio Drugs, 2013, 27(5):495-507. BOLOGNA L, GOTTI E, MANGANINI M, et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab . J Immunol, 2011, 186(6):3762-3769. ARNOLD D F, MISBAH S A. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose . N Engl J Med, 2008, 358(11):1109-1117. VALABREGA G, MONTEMURRO F, AGLIETTA M. Trastuzumab:mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer . Ann Oncol, 2007, 18(6):977-984. WAKANKAR A, CHEN Y, GOKARN Y, et al. Analytical methods for physicochemical characterization of antibody drug conjugates . MAbs, 2011, 3(2):161-172. ZHANG F, MENG S F. The quality control of therapeutic monoclonal antibody products . China Licensed Pharmacist(�й�ִҵҩʦ), 2013,10(1):25-30. TAN Q, GUO Q, FANG C, et al. Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products . MAbs, 2012, 4(6):761-774. TERNANT D, ARNOULT C, PUGNIERE M, et al. IgG1 allotypes influence the pharmacokinetics of therapeutic monoclonal antibodies through FcRn binding . J Immunol, 2016, 196(2):607-613. LIU B N. The technology progress of antibody-producing cell line development . China Biotechnol(�й����﹤����־), 2013, 33(6):111-116. LIU B N. The lasted development of large scale cell culture technology for commerical antibody manufacture . China Biotechnol(�й����﹤����־), 2013,33(7):103-111.
2017, Vol. 52 
